© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
May 09, 2025
The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.
Crinecerfont Reduces GC Dosing, Improves Androstenedione Levels Across Multiple Pediatric Subgroups
May 09, 2025
Data for GC reduction and improved A4 levels were consistent across subgroups stratified by sex, race, age, BMI, and baseline A4 levels, according to Neurocrine Biosciences.
Cervical Cancer Screening Best Practices for Physicians
May 09, 2025
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
Immunogenicity of Combined Flu/COVID-19 Vaccine Noninferior to Components in Older Adults
May 09, 2025
The investigational mRNA-1083 vaccine induced superior immune responses against all 4 flu strains in adults aged 50-64 years and against 3 in adults 65 and older.
Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
May 08, 2025
The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.
Rising Lp(a) Levels Increase Risk of Subsequent CVD Events in Adults with ASCVD, According to Large Real-World Study
May 08, 2025
Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.
Understanding Gaps in Patient Knowledge of Cervical Cancer Screening
May 08, 2025
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces
May 08, 2025
Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.
Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD
May 07, 2025
The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.
Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
May 07, 2025
EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.